Free tool
FAERS Monitor: Asmanex Hfa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205641 or its brand name (Asmanex Hfa, Mometasone Furoate). Reports on generic versions are filed under their own applications.
Reports
11,481
Serious
7,460
65% of reports
Hospitalization
3,247
Death reported
505
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,099
- drug ineffective968
- asthma945
- headache934
- cough818
- off label use797
- fatigue700
- pruritus652
- gastrooesophageal reflux disease603
- wheezing579
- nausea578
- hypersensitivity566
- pain552
- no adverse event548
- pneumonia533
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 57 |
| 2005 | 56 |
| 2006 | 56 |
| 2007 | 91 |
| 2008 | 150 |
| 2009 | 122 |
| 2010 | 145 |
| 2011 | 143 |
| 2012 | 145 |
| 2013 | 96 |
| 2014 | 139 |
| 2015 | 225 |
| 2016 | 382 |
| 2017 | 424 |
| 2018 | 897 |
| 2019 | 876 |
| 2020 | 840 |
| 2021 | 1,051 |
| 2022 | 1,262 |
| 2023 | 1,238 |
| 2024 | 1,058 |
| 2025 | 1,079 |
| 2026 | 949 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,678 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wheezingSignal | 579 | 18.1 | 16.7 | 9,245 |
| asthmaSignal | 945 | 15.4 | 14.5 | 12,709 |
| gastrooesophageal reflux diseaseSignal | 603 | 13.8 | 12.8 | 7,131 |
| hypersensitivitySignal | 566 | 5.6 | 5.2 | 2,147 |
| no adverse eventSignal | 548 | 5.6 | 5.1 | 2,054 |
| coughSignal | 818 | 5.4 | 5.0 | 2,924 |
| dyspnoeaSignal | 1,099 | 3.6 | 3.4 | 2,074 |
| pruritusSignal | 652 | 3.1 | 2.9 | 948 |
| pneumoniaSignal | 533 | 3.0 | 2.8 | 728 |
| headacheSignal | 934 | 2.7 | 2.6 | 1,053 |
| off label use | 797 | 1.7 | 1.6 | 222 |
| fatigue | 700 | 1.6 | 1.5 | 184 |
| pain | 552 | 1.6 | 1.5 | 144 |
| drug ineffective | 968 | 1.3 | 1.3 | 91 |
| nausea | 578 | 1.3 | 1.2 | 51 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.